Ramez N. Eskander, MD

Articles

Ongoing Clinical Trials for Patients With Endometrial Cancer: Looking Toward the Future

April 5th 2022

Experts highlight key ongoing trials and emerging therapies for patients with endometrial cancer.

Management of Adverse Events After Combination Lenvatinib/Pembrolizumab

March 29th 2022

Shared insight on the management of commonly observed adverse events in patients with endometrial cancer who are receiving combination lenvatinib/pembrolizumab.

Treatment Modification Rates for Combination Lenvatinib/Pembrolizumab

March 29th 2022

A brief review of treatment interruption, discontinuation, and dose modification rates in patients receiving combination lenvatinib/pembrolizumab in the KEYNOTE-775 trial or in the experts’ clinical practice.

The KEYNOTE-775 Trial: Efficacy of Combination Lenvatinib/Pembrolizumab in Endometrial Cancer

March 22nd 2022

Vicky Makker, MD, leads a discussion of efficacy data from the KEYNOTE-775 trial on combination lenvatinib/pembrolizumab in patients with endometrial cancer.

First-line Treatment Options for Advanced Endometrial Cancer

March 22nd 2022

A comprehensive overview of first-line treatment options for patients with advanced endometrial cancer.

Molecular Testing in Endometrial Cancer

March 15th 2022

Experts discuss how molecular testing can inform treatment selection and patient management for those with endometrial cancer.

Endometrial Cancer: A Global Problem

March 15th 2022

Vicky Makker, MD and Ramez Eskander, MD discuss the increasing global incidence of endometrial cancer.

Dr. Eskander on the Utility of Lymphadenectomy in Endometrial Cancer

August 25th 2021

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Dr. Eskander on Need for Biomarkers in Ovarian Cancer

February 21st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses the need for more effective biomarkers in the treatment of patients with ovarian cancer.

Dr. Eskander on Combination Approaches With Immunotherapy in Ovarian Cancer

February 1st 2019

Ramez N. Eskander, MD, assistant clinical professor, Department of Reproductive Medicine, University of California, San Diego Moores Cancer Center, discusses combination approaches with immunotherapy in ovarian cancer.